[Genetic analysis of a case with 11β hydroxylase deficiency caused by CYP11B2/CYP11B1 chimeric gene].
Lin. Yifan Y; Yang. Haihua H; Yuan. Shuxian S; Li. Dongxiao D; Wei. Haiyan H; Ma. Xiaocui X
Key Findings
- The child’s condition was misdiagnosed as 21‑hydroxylase deficiency but was actually 11β‑hydroxylase deficiency due to a CYP11B2/CYP11B1 chimeric gene.
- Comprehensive genetic testing (WES, RT‑PCR, Long‑PCR) identified the chimeric gene and a pathogenic CYP11B1 variant.
- Treatment with hydrocortisone and the GnRH agonist triptorelin effectively managed the early puberty and allowed normal growth and a healthy pregnancy.
Practical Outcomes
- For most biohackers, this case offers limited direct use, but it highlights the need for precise genetic testing when hormonal issues arise. It also shows that triptorelin can be used to control premature puberty in rare enzyme deficiency cases, though this isn’t a common protocol for general health optimization.
Summary
A 5‑year‑old boy was thought to have a common adrenal disorder but was actually found to have a rare genetic mix of two enzyme genes, causing early puberty and fast growth. Genetic tests pinpointed the exact mutation, and treatment with a steroid (hydrocortisone) plus a hormone drug (triptorelin) stopped the premature development and led to a healthy pregnancy later on.
Abstract
To analyze a child with 11β hydroxylase deficiency (11β-OHD) due to CYP11B2/CYP11B1 chimeric gene. Clinical data of the child who was admitted to Henan Children's Hospital on August 24, 2020 were retrospectively analyzed. Peripheral blood samples of the child and his parents were collected and subjected to whole exome sequencing (WES). Candidate variant was verified by Sanger sequencing. RT-PCR and Long-PCR were carried out to verify the presence of chimeric gene. The patient, a 5-year-old male, had featured premature development of secondary sex characteristics and accelerated growth, and was diagnosed with 21 hydroxylase deficiency (21-OHD). WES revealed that he has harbored a heterozygous c.1385T>C (p.L462P) variant of the CYP11B1 gene, in addition to a 37.02 kb deletion on 8q24.3. Based on the guidelines from the American College of Medical Genetics and Genomics (ACMG), the c.1385T>C (p.L462P) was rated as a likely pathogenic variant (PM2_Supporting+PP3_Moderate+PM3+PP4). The results of RT-PCR and Long-PCR suggested that CYP11B1 and CYP11B2 genes have recombined to form a CYP11B2 exon 1~7/CYP11B1 exon 7~9 chimeric gene. The patient was diagnosed as 11β-OHD and effectively treated with hydrocortisone and triptorelin. A healthy fetus was delivered following genetic counseling and prenatal diagnosis. 11β-OHD may be misdiagnosed as 21-OHD due to the potential CYP11B2/CYP11B1 chimeric gene, which will require multiple methods for the detection.
Study Information
pubmed
2023
2023-04-10T00:00:00.000Z
10.3760/cma.j.cn511374-20220902-00598
1